Jardiance Declared Best International Pharmaceutical Product 2018

Boehringer Ingelheim’s sodium-glucose co-transporter 2 (SGLT-2) inhibitor, Jardiance (empagliflozin), has been announced winner of the 2018 Prix Galien International Award in the category “Best Pharmaceutical Product”.

The Prix Galien Award is presented by the Galien Foundation to recognise and reward excellence in scientific innovation and outstanding achievement in improving the human condition through the development of innovative therapies. It is counted among the global health innovation industry’s most prized honours, and worldwide is regarded as the equivalent of the Nobel prize in biopharmaceutical and medical technology research.1,2  The nominees, selected by an independent committee of distinguished researchers and academics, must demonstrate tremendous potential to impact human health.2

Winners of the Prix Galien Award were announced on 28 November at an inaugural event in Dakar, Senegal; the first time the annual award has been presented on the African continent. Jardiance was selected from among 20 other innovative nominees, representing advancements in diabetes, spinal muscular atrophy and acquired immunodeficiency syndrome.1,2   

About Jardiance

The SGLT-2 inhibitors are a relatively new class of glucose-lowering agents and have been shown to confer significant benefits in terms of cardiovascular outcomes in patients with type 2 diabetes.3-5 Large randomised controlled clinical trials (RCTs) including a total of more than 34 000 patients demonstrated that this class of treatment significantly reduces both incidence of cardiovascular events and progression of renal disease.3-6  In particular the three agents in this class (empagliflozin, canagliflozin and dapagliflozin) have all been associated with a significant 27-35% reduction in the rate of hospitalisation for heart failure.3-5 However, Jardiance is the only SGLT-2 inhibitor that has been shown to significantly reduce the incidence of cardiovascular death.3-5

Most recently, results of the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study presented at the American Heart Association 2018 Scientific Sessions in November and including data derived from 35 000 patients, provided reassurance that the benefits of Jardiance are reflected also in day-to-day clinical practice.7 Compared with dipeptidyl-peptidase-4 (DPP-4) inhibitors, empagliflozin was associated with an overall 44% relative risk reduction in hospitalisation for heart failure. This treatment effect remained consistent regardless of history of cardiovascular disease, reiterating that the benefits of Jardiance extend across a broad range of patients with differing degrees of cardiovascular risk. 7

“We are thrilled that the international community has recognised the benefits of Jardiance”, says Dr Michael Klein, Medical Director of Boehringer Ingelheim, South Africa. “Presentation of the award on African soil this year is particularly fitting and representative of our sincere commitment to health and wellbeing of the peoples of South Africa and the continent in general.”

References
  1. Galien Foundation. https://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2018-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300686964.html. Accessed 4 December 2018.
  2. Galien Foundation. https://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2018-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300686964.html. Accessed 4 December 2018.
  3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes.  N Engl J Med 2015; 373:2117-2128.
  4. Neal B, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657.
  5. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2018. Published online 10 Nov 2018. DOI: 10.1056/NEJMoa1812389
  6. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323‐334.
  7. Patorno E, Pawar A, Frnklin JM, et al. Empagliflozin and the risk of heart failure hospitalisation in routine clinical care: A first analysis from the Empagliflozin Comparative Effectiveness And Safety (EMPRISE) Study. Abstract and poster presented at the American Heart Association (AHA) Scientific Sessions, 10-12 Nov 2018, Chicago, IL, USA.
Wildcard SSL